Anal canal cancer

This phase II trial is testing whether a lower dose of chemotherapy plus radiation can work as well as the standard dose for early-stage anal cancer. The study includes 252 adults with T1-2N0M0 anal cancer. The goal is to see if the gentler approach controls the disease while imp…

This phase 3 trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (carboplatin and paclitaxel) helps people with metastatic anal cancer live longer without their disease getting worse. About 205 adults with inoperable or recurrent anal cancer …

This phase III trial tests whether adding the immunotherapy drug nivolumab after standard combined modality therapy (chemo and radiation) can improve outcomes for patients with high-risk stage IIB-IIIC anal cancer. About 344 participants will receive nivolumab or a placebo. The m…

This phase 2 trial is testing whether adding the immunotherapy drug durvalumab to the usual chemotherapy and radiation treatment can help people with locally advanced anal cancer stay cancer-free longer. The study includes about 180 adults with stage IIB–IIIC anal cancer. Partici…

This study tests two immunotherapy drugs, nivolumab and ipilimumab, in people with anal cancer that has spread and not responded to prior treatment. The goal is to see if these drugs can shrink tumors or slow cancer growth. About 143 adults with advanced squamous cell carcinoma o…

This phase 2 trial is testing whether adjusting treatment based on risk level can improve outcomes for people with HIV who have anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab after sta…

This study is testing whether doing a special PET scan during radiation treatment can help doctors adjust the plan to better target tumors and spare healthy tissue. It involves 90 adults with cervical, vulvar, esophageal, or anal cancer. The goal is to see if this approach improv…